- Organizations: DefEYE, Inc
Business
DefEYE and Celularity partner to advance ophthalmic biologics portfolios
Collaboration features a multi-million dollar investment in DefEYE as well as an exclusive sublicense of Celularity’s BIOVANCE amnion-derived ocular allografts.Business